Gut microbiome predicts personalized responses to dietary fiber in prediabetes: a randomized, open-label trial.

ABSTRACT: Gut microbiota contributes to prediabetes progression, however, whether microbiota features can guide targeted prevention and treatment for diabetes requires validation through large-scale clinical trials. Here, in a randomized, open-label trial, we randomly assigned 802 prediabetic subjects to a usual care control group (patient education and dietary recommendations, n = 393) or a dietary fiber intervention group (n = 409) for 6 months. The primary outcome was the percentage change in whole-blood HbA1c, and secondary outcomes were the changes in other glucose, insulin, lipid, liver and kidney function, and anthropometric parameters. There were no statistically significant differences in the primary and secondary outcomes between groups. In post-hoc analysis, we reclassified subjects into

SUBMITTER: Song D 

PROVIDER: S-EPMC12749054 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature